Literature DB >> 20859312

Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective.

Laxmaiah Manchikanti1, Bert Fellows, Hary Ailinani, Vidyasagar Pampati.   

Abstract

The treatment of chronic pain, therapeutic opioid use and abuse, and the nonmedical use of prescription drugs have been topics of intense focus and debate. After the liberalization of laws governing opioid prescribing for the treatment of chronic non-cancer pain by state medical boards in the late 1990s, and with the introduction of new pain management standards implemented by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) in 2000, opioids, in general, and the most potent forms of opioids including Schedule II drugs, in particular, have dramatically increased. Despite the escalating use and abuse of therapeutic opioids, nearly 15 to 20 years later the scientific evidence for the effectiveness of opioids for chronic non-cancer pain remains unclear. Concerns continue regarding efficacy; problematic physiologic effects such as hyperalgesia, hypogonadism and sexual dysfunction; and adverse side effects - especially the potential for misuse and abuse - and the increase in opioid-related deaths. Americans, constituting only 4.6% of the world's population, have been consuming 80% of the global opioid supply, and 99% of the global hydrocodone supply, as well as two-thirds of the world's illegal drugs. Retail sales of commonly used opioid medications (including methadone, oxycodone, fentanyl base, hydromorphone, hydrocodone, morphine, meperidine, and codeine) have increased from a total of 50.7 million grams in 1997 to 126.5 million grams in 2007. This is an overall increase of 149% with increases ranging from 222% for morphine, 280% for hydrocodone, 319% for hydromorphone, 525% for fentanyl base, 866% for oxycodone, to 1,293% for methadone. Average sales of opioids per person have increased from 74 milligrams in 1997 to 369 milligrams in 2007, a 402% increase. Surveys of nonprescription drug abuse, emergency department visits for prescription controlled drugs, unintentional deaths due to prescription controlled substances, therapeutic use of opioids, and opioid abuse have been steadily rising. This manuscript provides an updated 10-year perspective on therapeutic use, abuse, and non-medical use of opioids and their consequences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859312

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  167 in total

1.  Prescription of opioids for opioid-naive medical inpatients.

Authors:  Sharan Lail; Kelly Sequeira; Jenny Lieu; Irfan A Dhalla
Journal:  Can J Hosp Pharm       Date:  2014-09

Review 2.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

3.  Patterns of prescription opioid abuse and comorbidity in an aging treatment population.

Authors:  Theodore J Cicero; Hilary L Surratt; Steven Kurtz; M S Ellis; James A Inciardi
Journal:  J Subst Abuse Treat       Date:  2011-08-09

4.  Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal.

Authors:  Virginia D McLane; Ivy Bergquist; James Cormier; Deborah J Barlow; Karen L Houseknecht; Edward J Bilsky; Ling Cao
Journal:  Life Sci       Date:  2017-07-16       Impact factor: 5.037

5.  Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy.

Authors:  Tracy-Ann Moo; Kate R Pawloski; Varadan Sevilimedu; Jillian Charyn; Brett A Simon; Lisa M Sclafani; George Plitas; Andrea V Barrio; Laurie J Kirstein; Kimberly J Van Zee; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2020-07-30       Impact factor: 5.344

Review 6.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

7.  Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice.

Authors:  Peyman Sahbaie; Xiaoyou Shi; Xiangqi Li; Deyong Liang; Tian-Zhi Guo; Yanli Qiao; David C Yeomans; Wade S Kingery; J David Clark
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

8.  Psychosocial Correlates of Clinicians' Prescription Drug Monitoring Program Utilization.

Authors:  John A Pugliese; Garen J Wintemute; Stephen G Henry
Journal:  Am J Prev Med       Date:  2018-03-17       Impact factor: 5.043

9.  Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio.

Authors:  Robert G Carlson; Ramzi W Nahhas; Raminta Daniulaityte; Silvia S Martins; Linna Li; Russel Falck
Journal:  Drug Alcohol Depend       Date:  2013-10-23       Impact factor: 4.492

10.  A prospective study of nonmedical use of prescription opioids during adolescence and subsequent substance use disorder symptoms in early midlife.

Authors:  Sean Esteban McCabe; Philip T Veliz; Carol J Boyd; Ty S Schepis; Vita V McCabe; John E Schulenberg
Journal:  Drug Alcohol Depend       Date:  2018-11-15       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.